Search Results - Michael D. Cameron

Refine Results
  1. 1
    Metabolism considerations for kinase inhibitors in cancer treatment

    Metabolism considerations for kinase inhibitors in cancer treatment by Derek R. Duckett, Michael D. Cameron

    Published 2010
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile

    Cytochrome P450-Mediated Bioactivation of the Epidermal Growth Factor Receptor Inhibitor Erlotinib to a Reactive Electrophile by Xiaohai Li, Theodore M. Kamenecka, Michael D. Cameron

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways

    Characterization of Dasatinib and Its Structural Analogs as CYP3A4 Mechanism-Based Inactivators and the Proposed Bioactivation Pathways by Xiaohai Li, Yuanjun He, Claudia Ruiz, Marcel Koenig, Michael D. Cameron

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Genetic Regulation of Behavioral and Neuronal Responses to Fluoxetine

    Genetic Regulation of Behavioral and Neuronal Responses to Fluoxetine by Brooke H. Miller, Laura E. Schultz, Anisha Gulati, Michael D. Cameron, Mathew T. Pletcher

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Insular hypocretin transmission regulates nicotine reward

    Insular hypocretin transmission regulates nicotine reward by Jonathan A. Hollander, Qun Lu, Michael D. Cameron, Theodore M. Kamenecka, Paul J. Kenny

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease

    JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease by Candice E. Crocker, Susan Khan, Michael D. Cameron, H.A. Robertson, George S. Robertson, Philip V. LoGrasso

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Orexin-1 Receptor Mediation of Cocaine Seeking in Male and Female Rats

    Orexin-1 Receptor Mediation of Cocaine Seeking in Male and Female Rats by Luyi Zhou, Shannon M. Ghee, Clifford Chan, Li Lin, Michael D. Cameron, Paul J. Kenny, Ronald E. See

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Precise small-molecule recognition of a toxic CUG RNA repeat expansion

    Precise small-molecule recognition of a toxic CUG RNA repeat expansion by Suzanne G. Rzuczek, Lesley A. Colgan, Yoshio Nakai, Michael D. Cameron, Denis Furling, Ryohei Yasuda, Matthew D. Disney

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORα and RORγ

    Identification of SR1078, a Synthetic Agonist for the Orphan Nuclear Receptors RORα and RORγ by Yongjun Wang, Naresh Kumar, Philippe Nuhant, Michael D. Cameron, Monica A. Istrate, William Roush, Patrick R. Griffin, Thomas P. Burris

    Published 2010
    Get full text
    Carta
    Save to List
    Saved in:
  10. 10
    Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains

    Evaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strains by Cristina S. Benton, Brooke H. Miller, Sean Skwerer, Oscar Suzuki, Laura E. Schultz, Michael D. Cameron, J. S. Marron, Mathew T. Pletcher, Tim Wiltshire

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use

    Nonmuscle myosin IIB as a therapeutic target for the prevention of relapse to methamphetamine use by Erica J. Young, Ashley M. Blouin, Sherri B. Briggs, Stephanie E. Daws, Li Lin, Michael D. Cameron, Gavin Rumbaugh, Courtney A. Miller

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription

    An Analog of the Natural Steroidal Alkaloid Cortistatin A Potently Suppresses Tat-Dependent HIV Transcription by Guillaume Mousseau, Mark A. Clementz, Wendy Bakeman, Nisha Nagarsheth, Michael D. Cameron, Jun Shi, Phil S. Baran, Rémi Fromentin, Nicolas Chomont, Susana Valente

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein

    Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein by Qingkai Yang, Xianming Deng, Bingwen Lu, Michael D. Cameron, Colleen Fearns, Matthew P. Patricelli, John R. Yates, Nathanael S. Gray, Jiing‐Dwan Lee

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents

    Rational Development of 4-Aminopyridyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 as Anti-Chagas Agents by Jun Yong Choi, Cláudia M. Calvet, Shamila S. Gunatilleke, Claudia Ruiz, Michael D. Cameron, James H. McKerrow, Larissa M. Podust, William Roush

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    S1P<sub>1</sub> Receptor Modulation with Cyclical Recovery from Lymphopenia Ameliorates Mouse Model of Multiple Sclerosis

    S1P<sub>1</sub> Receptor Modulation with Cyclical Recovery from Lymphopenia Ameliorates Mouse Model of Multiple Sclerosis by Pedro J. Gonzalez‐Cabrera, Stuart M. Cahalan, Nhan Trung Nguyen, Gor Sarkisyan, Nora B. Leaf, Michael D. Cameron, Tomoyuki Kago, Hugh Rosen

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening

    Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening by Shaun P. Brothers, S. Adrian Saldanha, Timothy Spicer, Michael D. Cameron, Becky A. Mercer, Peter Chase, Patricia McDonald, Claes Wahlestedt, Peter Hodder

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    <i>R</i>-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against <i>Trypanosoma cruzi</i>

    <i>R</i>-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against <i>Trypanosoma cruzi</i> by Jun Yong Choi, Cláudia M. Calvet, Débora Vieira, Shamila S. Gunatilleke, Michael D. Cameron, James H. McKerrow, Larissa M. Podust, William Roush

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Design of a small molecule against an oncogenic noncoding RNA

    Design of a small molecule against an oncogenic noncoding RNA by Sai Pradeep Velagapudi, Michael D. Cameron, Christopher L. Haga, Laura H. Rosenberg, M. Lafitte, Derek R. Duckett, Donald G. Phinney, Matthew D. Disney

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics

    Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics by Cullen L. Schmid, Nicole Kennedy, Nicolette C. Ross, Kimberly M. Lovell, Zhizhou Yue, Jenny Morgenweck, Michael D. Cameron, Thomas D. Bannister, Laura Bohn

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias

    Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias by Nicole Kennedy, Cullen L. Schmid, Nicolette C. Ross, Kimberly M. Lovell, Zhizhou Yue, Yen‐Ting Chen, Michael D. Cameron, Laura Bohn, Thomas D. Bannister

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: